Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).

被引：2
|
作者：
Labriola, Matthew
Zhu, Jason
Gupta, Rajan
McCall, Shannon
Jackson, Jennifer
White, James R.
Weingartner, Elizabeth
Kong, Eric
Simone, Peter
Papp, Eniko
Gerding, Kelly
Simmons, John
George, Daniel J.
Zhang, Tian
机构：
[1] Duke Med Ctr, Durham, NC USA
[2] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Personal Genome Diagnost Inc, Baltimore, MD USA
[5] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
[6] Duke Univ, Canc Inst, Durham, NC USA
[7] Duke Univ, Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e16079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16079
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [2] Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
    Labriola, Matthew Kyle
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    Kong, Eric F.
    White, James R.
    Cerqueira, Gustavo
    Gerding, Kelly
    Simmons, John K.
    George, Daniel
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [3] Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC).
    Maia, Manuel C.
    Almeida, Lorena
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [4] Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.
    Osipov, Arsen
    Popovic, Aleksandra
    Hopkins, Alexander
    Frampton, Garrett M.
    Albacker, Lee A.
    Azad, Nilofer Saba
    Laheru, Daniel A.
    Zheng, Lei
    Jaffee, Elizabeth M.
    Yarchoan, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers
    Chen, San-chi
    Tan, Kien-Thiam
    Chen, Ming-Huang
    Hung, Yi-Ping
    Hsieh, Yi-Lin
    Jan, Yi-Hua
    Chao, Yee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers
    Hsieh, Yi-Lin
    Yu, Pei-Ning
    Jan, Yi-Hua
    Lai, Meng-Shao
    Wang, Woei-Fuh
    Zhuo, De-Wei
    Chen, Shu-Jen
    Cheng, Jen-Hao
    Tan, Kien Thiam
    Su, Yu-Li
    CANCER RESEARCH, 2020, 80 (16)
  • [7] Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
    Burcher, Kimberly M.
    Lantz, Jeffrey W.
    Gavrila, Elena
    Abreu, Arianne
    Burcher, Jack T.
    Faucheux, Andrew T.
    Xie, Amy
    Jackson, Clayton
    Song, Alexander H.
    Hughes, Ryan T.
    Lycan, Thomas, Jr.
    Bunch, Paul M.
    Furdui, Cristina M.
    Topaloglu, Umit
    D'Agostino, Ralph T. B., Jr.
    Zhang, Wei
    Porosnicu, Mercedes
    CANCERS, 2021, 13 (22)
  • [8] Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
    Meza, Luis A.
    Choi, Yongwook
    Govindarajan, Ameish
    Dizman, Nazli
    Zengin, Zeynep Busra
    Hsu, Joann
    Salgia, Nicholas
    Salgia, Sabrina
    Malhotra, Jasnoor
    Chawla, Neal Shiv
    Chehrazi-Raffle, Alex
    Muddasani, Ramya
    Castro, Daniela V.
    Chan, Agnes
    Zhang, Guangfa
    Byron, Sara A.
    Highlander, Sarah K.
    Schork, Nick
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB).
    Jindal, Tanya
    Zhu, Xiaolin
    Zhang, Li
    Reyes, Kevin R.
    Deshmukh, Prianka
    de Kouchkovsky, Ivan
    Kumar, Vipul
    Maldonado, Edward
    Shipp, Chase
    Kwon, Daniel H.
    Borno, Hala
    Bose, Rohit
    Desai, Arpita
    Aggarwal, Rahul Raj
    Porten, Sima P.
    Small, Eric Jay
    Fong, Lawrence
    Chou, Jonathan
    Friedlander, Terence W.
    Koshkin, Vadim S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [10] Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?
    Albiges, Laurence
    Flippot, Ronan
    Escudier, Bernard
    EUROPEAN UROLOGY, 2021, 79 (06) : 793 - 795
12345